Edrienny Patrícia Alves Accioly Rocha1,2, Mandy Vogel1,3, Juraj Stanik3,4, Diana Pietzner1,2, Anja Willenberg5, Antje Körner6, Wieland Kiess1,2. 1. University of Leipzig, LIFE Child Leipzig Research Center for Civilization Diseases, Leipzig, Germany. 2. University of Leipzig, Hospital for Children and Adolescents, Leipzig, Germany. 3. University of Leipzig, Centre of Paediatric Research (CPL), Leipzig, Germany. 4. Department of Pediatrics, Medical Faculty, Comenius University, and Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia. 5. University of Leipzig, Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics (ILM), Leipzig, Germany. 6. Hospital for Children and Adolescents, Department of Women and Child Health, University Hospitals, University of Leipzig, Leipzig, Germany.
Abstract
BACKGROUND: Metabolically healthy obesity (MHO) refers to those individuals who do not show cardiometabolic abnormalities. Our aim was to identify potential clinical and metabolic indicators that may help to distinguish between metabolically healthy and unhealthy individuals amongst overweight and obese children and adolescents. METHODS: The study involved 246 overweight/obese and 212 normal-weight individuals enrolled in the LIFE Child study, aged between 6 and 18 years. Overweight/obese individuals without cardiovascular risk factors (fasting serum lipids, blood pressure, and glucose) were classified as MHO. Individuals meeting 1 or more criteria of cardiovascular risk factors were classified as metabolically unhealthy obesity (MUO). RESULTS: Among the 246 overweight/obese individuals, 173 (70%) were MHO and 73 (30%) were MUO. The MHO individuals were younger, more likely to be male, and had lower BMI SDS. In the logistic regression models, uric acid (UA) SDS (OR 1.61, 95% CI 1.1-2.6, p = 0.004), waist circumference SDS (OR 2.50, 95% CI 1.2-6.4, p = 0.017), and C-peptide (OR 4.05, 95% CI 3.5-91, p = 0.003) were significant indicators of MUO. CONCLUSION: Our results suggest that nearly one-third of overweight/obese children are already identified as MUO. Serum levels of UA can be used as an indicator of unhealthy obesity in youth, where lower levels of UA indicate a lower risk and higher levels suggest a higher risk of MUO. We note that the relevance of identifying potential indicators remains the first most important step in future clinical research.
BACKGROUND: Metabolically healthy obesity (MHO) refers to those individuals who do not show cardiometabolic abnormalities. Our aim was to identify potential clinical and metabolic indicators that may help to distinguish between metabolically healthy and unhealthy individuals amongst overweight and obesechildren and adolescents. METHODS: The study involved 246 overweight/obese and 212 normal-weight individuals enrolled in the LIFE Child study, aged between 6 and 18 years. Overweight/obese individuals without cardiovascular risk factors (fasting serum lipids, blood pressure, and glucose) were classified as MHO. Individuals meeting 1 or more criteria of cardiovascular risk factors were classified as metabolically unhealthy obesity (MUO). RESULTS: Among the 246 overweight/obese individuals, 173 (70%) were MHO and 73 (30%) were MUO. The MHO individuals were younger, more likely to be male, and had lower BMI SDS. In the logistic regression models, uric acid (UA) SDS (OR 1.61, 95% CI 1.1-2.6, p = 0.004), waist circumference SDS (OR 2.50, 95% CI 1.2-6.4, p = 0.017), and C-peptide (OR 4.05, 95% CI 3.5-91, p = 0.003) were significant indicators of MUO. CONCLUSION: Our results suggest that nearly one-third of overweight/obesechildren are already identified as MUO. Serum levels of UA can be used as an indicator of unhealthy obesity in youth, where lower levels of UA indicate a lower risk and higher levels suggest a higher risk of MUO. We note that the relevance of identifying potential indicators remains the first most important step in future clinical research.
Authors: Margot De Spiegeleer; Ellen De Paepe; Lieven Van Meulebroek; Inge Gies; Jean De Schepper; Lynn Vanhaecke Journal: Mol Med Date: 2021-11-06 Impact factor: 6.354
Authors: Ruziana Mona Wan Mohd Zin; Muhammad Yazid Jalaludin; Abqariyah Yahya; Ahmad Kamil Nur Zati Iwani; Fuziah Md Zain; Janet Yeow Hua Hong; Abdul Halim Mokhtar; Wan Nazaimoon Wan Mohamud Journal: Front Endocrinol (Lausanne) Date: 2022-08-22 Impact factor: 6.055